Analyst Consensus ?
ConsensusBuy6 ratings
Bullish583.3%
Neutral116.7%
Bearish00.0%
Takeda Pharmaceutical Company Limited · TAK · FY2026 Q3 · Calendar Q1 2026
Takeda maintains profit outlook despite revenue pressure
Takeda's near-term growth case rests on three late-stage launches and continued cost discipline, but generic erosion, launch spending, reimbursement, and ENTYVIO pricing remain material offsets.
Reported Before market openNYSEHealthcare
$66.81B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.48
Consensus $0.55
EPS surprise
-12.7%
Reported versus consensus
Reported revenue
$7.73B
Consensus $7.54B
Revenue surprise
+2.5%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.9%
Event window
SPY move
-0.2%
Same window
Abnormal move
+3.1%
Stock minus SPY
Volume
1.6×
Versus trailing sessions
Subsequent drift
+9.2%
Up to 20 sessions
TAKSPY benchmark
Ask FN2 about TAK FY2026 Q3
Transcript, numbers and history already loaded
Why did TAK rise 2.9% after missing EPS estimates in FY2026 Q3?What changed in TAK's guidance and outlook in FY2026 Q3?Give me the bull and bear case for TAK after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, Takeda kept core operating profit and EPS guidance unchanged but lowered revenue guidance to a low single-digit decline. Management added detail on positive Phase III results, planned filings for oveporexton and rusfertide, zasocitinib preparations, and a CEO transition with organizational changes.
Guidance delta
Revenue guidance was lowered to a low single-digit decline; core operating profit and EPS guidance remained unchanged.
Key takeaways
- Management said Q3 performance exceeded expectations despite VYVANSE generic erosion, supported by cost discipline.
- Oveporexton, rusfertide, and zasocitinib had positive Phase III results and are planned for near-term launches.
- ENTYVIO Pen's inclusion in Medicare IRA price negotiation creates a potential future pricing headwind.
Management priorities
- Prepare filings and launch activities for oveporexton, rusfertide, and zasocitinib.
- Maintain cost discipline while funding pipeline development and product launches.
- Improve U.S. commercial execution and use AI and advanced technologies to streamline processes.
Follow TAK with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Outperform | Outperform | Maintain | May 16, 2023 |
| B of A Securities | Buy | Neutral | Upgrade | Mar 16, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jul 19, 2022 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Oct 7, 2021 |
| JP Morgan | Overweight | Overweight | Maintain | Mar 11, 2020 |
| Jefferies | Buy | Buy | Maintain | Sep 24, 2019 |
Track every rating change on TAK the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationTakeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.…
Historical context
All TAK earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +10.0% | BrightSpring posts strong Q3 growth as pharmacy leads |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the TAK recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T09:20:40.114789+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.